Results from a recent retrospective study from France, published in the journal Oncology, have shown that stereotactic radiotherapy is safe and effective for metastatic renal cell carcinoma (RCC) patients with metastases in one or two other parts of the body (oligometastatic or oligoprogressive). Stereotactic radiotherapy may also delay the start or change of systemic (drug) therapy.
In this study, 188 patients were treated with stereotactic radiotherapy for 252 RCC metastases, mostly in the brain and spine. For the whole patient population, median progression-free survival (PFS) was 8.5 months, and overall survival (OS) was 29.2 months. For patients treated for oligoprogressive/oligometastatic disease, the median PFS and OS were 8.6/7.6 and 23.2/33.9 months, respectively. Acute and late severe toxicities were reported in 5 (2.6%) patients.